Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Sangamo's new zinc finger protein transcription factor neuroprotective in spinal injury model

Nov. 27, 2008

Antiallodynic activity of Adolor's novel potent NGF-TrkA antagonist

Nov. 26, 2008

UWA-0121 extends L-DOPA activity in primate model of Parkinson's disease

Nov. 26, 2008

MK-677 does not meet efficacy endpoints in a phase II Alzheimer's disease study

Nov. 26, 2008

DepoMed enters into exclusive license agreement with Solvay for DM-1796

Nov. 26, 2008

ChemDiv and Avineuro extend collaboration in Alzheimer's disease

Nov. 26, 2008

Neuromed completes enrollment for phase III trial of NMED-1077 in chronic low back pain

Nov. 26, 2008

Hemispherx enters major contract with Lovelace Respiratory Research Institute

Nov. 26, 2008

Xenazine tablets available in U.S. for chorea associated with HD

Nov. 25, 2008

Valdoxan receives CHMP positive opinion for major depressive disorder

Nov. 25, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...